•
ZN
ZNTL
Zentalis Pharmaceuticals, Inc. Common Stock
yahooPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
191.01M
Volume
814.62K
52W High
$3.95
52W Low
$1.01
Open
$0.00
Prev Close
$2.87
Day Range
0.00 - 0.00
About Zentalis Pharmaceuticals, Inc. Common Stock
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Latest News
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026
Benzinga•Jan 12
Incyclix Bio Expands Board of Directors with Appointment of Dr. Kimberly Blackwell
GlobeNewswire Inc.•Dec 17
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Sep 2
Zentalis (ZNTL) Q2 Loss Narrows 70%
The Motley Fool•Aug 7
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Jul 1
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Jun 2
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.•Apr 1
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
GlobeNewswire Inc.•Mar 15